Drug class
Hydrazine-derived monoamine oxidase inhibitor (MAOI); historical antidepressant and antitubercular agent
Mechanism of action
Irreversibly inhibits monoamine oxidase, reducing breakdown of serotonin, noradrenaline and dopamine and increasing monoaminergic neurotransmission. The same non-selective MAO inhibition contributes to clinically significant interactions and toxicity.
General use cases
- Historically introduced for treatment of depressive illness and originally used as an antitubercular agent. It is no longer a routine contemporary antidepressant because of serious hepatotoxicity and other safety concerns; this entry is historical pharmacology, not a current treatment recommendation.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
